CN117164562A - Oxopyridazine compound and preparation method and application thereof - Google Patents
Oxopyridazine compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN117164562A CN117164562A CN202311149889.5A CN202311149889A CN117164562A CN 117164562 A CN117164562 A CN 117164562A CN 202311149889 A CN202311149889 A CN 202311149889A CN 117164562 A CN117164562 A CN 117164562A
- Authority
- CN
- China
- Prior art keywords
- strokes
- compound
- pharmaceutically acceptable
- stereoisomer
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims abstract description 6
- 200000000007 Arterial disease Diseases 0.000 claims abstract description 5
- 208000006011 Stroke Diseases 0.000 claims description 17
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 6
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000009424 thromboembolic effect Effects 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 206010014498 Embolic stroke Diseases 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 2
- 206010038563 Reocclusion Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000002266 amputation Methods 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 208000021328 arterial occlusion Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 201000002818 limb ischemia Diseases 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 108010080805 Factor XIa Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000012224 working solution Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000010100 anticoagulation Effects 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- -1 oxo-pyridine compound Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- DWOZNANUEDYIOF-UHFFFAOYSA-L 4-ditert-butylphosphanyl-n,n-dimethylaniline;dichloropalladium Chemical compound Cl[Pd]Cl.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 DWOZNANUEDYIOF-UHFFFAOYSA-L 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 108010074864 Factor XI Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001184 polypeptide Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- CUJCDCSWBJDFNI-UHFFFAOYSA-N 3-methoxy-1h-pyridazin-6-one Chemical compound COC1=CC=C(O)N=N1 CUJCDCSWBJDFNI-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000110847 Kochia Species 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical class [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000623 proteins and genes Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound shown in a formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof. The invention also provides application of the compound, stereoisomer or pharmaceutically acceptable salt thereof in preparing medicaments for treating and/or preventing diseases related to the F XI a receptor, in particular application in preparing medicaments for treating and/or preventing cerebrovascular arterial diseases and/or peripheral arterial diseases, and has better and safer medicinal effects.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to an oxo-pyridine compound or salts and isomers thereof, a preparation method thereof and application thereof in preparing medicaments for treating and/or preventing diseases related to an XI a receptor, in particular to application in preparing medicaments for treating cerebrovascular arterial diseases and/or peripheral arterial diseases and the like.
Background
Thromboembolic diseases are diseases caused by abnormal blood clots formed in blood vessels of humans and animals during survival, and clinically may be manifested as myocardial infarction, stroke, deep Vein Thrombosis (DVT), pulmonary embolism, atrial fibrillation, cerebral infarction, etc., taking millions of people worldwide each year. Factor XI (FXI) is a plasma serine protease zymogen necessary for maintaining the endogenous pathway, and activated to form activated factor XIa (FXIa) plays a key role in the amplification of the coagulation cascade. Therefore, drugs against FXIa targets block endogenous pathways and inhibit amplification of the coagulation cascade, thus having antithrombotic effects.
The reported FXIa inhibitors mainly comprise monoclonal antibodies, antisense oligonucleotides, chemical small molecules, polypeptides or protein or polypeptide mimics and the like. Currently, milvexin, developed in conjunction with robustly, has completed clinical phase II trials, which have shown less risk of bleeding. Phase I clinical trials of the intravenous injection of the small molecule FXIa inhibitor BMS-962122 have been completed and development has been suspended. The small molecule oral FXIa inhibitor ONO-7684 developed by Japan Kochia company enters clinical phase I study. BAY-2433334 developed by Bayer has completed a clinical phase II trial and is currently the most promising small molecule FXIa inhibitor. The monoclonal antibody and the antisense oligonucleotide need to be injected and administrated, and have the defects of high price, slow effect, possibly difficult control and the like, and the chemical small molecules have the advantages of relatively good oral bioavailability, better patient compliance and the like.
Therefore, the research and development of new FXIa small molecule inhibitor drugs with safety, effectiveness, good specificity and strong activity can be used for overcoming the defect that the current clinical anticoagulation anti-thrombus drugs are easy to cause bleeding complications and meeting the clinical unmet demands.
Disclosure of Invention
The compound is a novel oxo-pyridine compound, and the compound of the embodiment of the invention shows good anticoagulation effect, in-vitro affinity to the FexI a and in-vivo drug generation.
In one aspect, the present invention provides a compound of formula (i), a stereoisomer or a pharmaceutically acceptable salt thereof:
further, the pharmaceutically acceptable salt is a metal salt.
Further, the metal salt is selected from sodium salt, potassium salt, calcium salt, lithium salt, and magnesium salt.
In another aspect, the present invention provides a pharmaceutical composition of the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof, which composition further comprises a pharmaceutically acceptable carrier and/or adjuvant.
In a third aspect, the present invention provides a process for the preparation of the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof, comprising the following route:
。
in a fourth aspect, the present invention also provides the use of any one of the above compounds, stereoisomers or pharmaceutically acceptable salts or compositions thereof, for the preparation of a medicament for treating and/or preventing diseases associated with the F xi a receptor.
Further, the above-mentioned diseases related to the F XI a receptor are selected from thrombosis or thromboembolic related disorders.
Further, the above-mentioned diseases related to the F XI a receptor are selected from cerebrovascular arterial diseases and/or peripheral arterial diseases.
Further, the above-mentioned cerebrovascular arterial diseases include, but are not limited to, transient Ischemic Attacks (TIAs), ischemic strokes or events that lead to thrombosis and/or thromboembolic origin of strokes or TIAs; such peripheral arterial disease includes, but is not limited to, peripheral arterial occlusion, acute limb ischemia, amputation, reocclusion and restenosis following interventions (e.g., angioplasty, stent implantation or surgery and bypass), and/or stent thrombosis.
Further, the ischemic stroke includes, but is not limited to, cardiac stroke, non-cardiac stroke, stroke due to aortic or arteriolar diseases, stroke due to adventitious causes, cryptogenic stroke, embolic stroke, or embolic stroke of adventitious origin.
Further, the above-mentioned cardiac strokes include, but are not limited to, strokes due to atrial fibrillation; such non-cardiac strokes include, but are not limited to, lacunar strokes.
The beneficial effects are that: compared with the prior art, the invention has good FXIa inhibition effect and anti-human plasma coagulation effect, and in vivo pharmacokinetics of rats shows that the invention has higher AUC and Cmax, and has quicker metabolism, thus avoiding the risk of increasing bleeding due to long-time effect.
Detailed Description
The present invention will be described in further detail with reference to the following examples and experimental examples, which are only for illustrating the technical scheme of the present invention, but not for limiting the present invention, and any equivalent substitution in the art according to the disclosure of the present invention shall fall within the scope of the present invention.
The structure of the compound is nuclear magnetic resonance 1 H NMR) or liquid mass spectrometry (LC-MS).
The liquid chromatography-mass spectrometer (LC-MS) is Agilent G6120B (matched with liquid phase Agilent 1260); nuclear magnetic resonance apparatus 1 H NMR) of Bruker AVANCE-400 or Bruker AVANCE-800, nuclear magnetic resonance 1 H NMR) shift [ ]δ) Given in parts per million (ppm), the internal standard is Tetramethylsilane (TMS), the chemical shift is 10 -6 (ppm) is given as a unit.
The term "room temperature" according to the invention means a temperature between 10 and 30 ℃.
Example 1: preparation of (S) -4- (2- (4- (5-chloro-2- (1H-tetrazol-1-yl) phenyl) -3- (methoxy-d 3) -6-oxopyridazin-1 (6H) -yl) butyramide) -2-fluoro-N- (methyl-d 3) benzamide (compound 1):
step 1: preparation of intermediate b
6-methoxypyridazin-3-ol (2 g,15.8 mmol) was taken, dissolved by adding 40ml DMF, cesium carbonate (10.3 g,31.6 mmol) was added, cooled to 0℃and deuterated iodomethane (3.5 g,24.1 mmol) was added dropwise over about 30 minutes, and the reaction was stirred at room temperature for 4 hours after the addition. EA, water, extraction, water washing, saturated brine washing, anhydrous sodium sulfate drying, filtration, evaporation of the solvent, column chromatography purification, 2g of intermediate b were obtained. Yield: 88.42%, HPLC purity: 98.81%.
ESI-MS:m/z=144.1 (M+H) + 。
Step 2: preparation of intermediate c
Diisopropylamine (1.7 g,16.8 mmol) was dissolved in 20ml THF, cooled to below-60℃and added dropwise with 6.4ml of 2.5M n-butyllithium-n-hexane solution over about 1 hour, followed by stirring at-60℃for 15 minutes, followed by adding dropwise with 5ml THF solution of compound b (2 g,14.0 mmol) for about 1 hour, followed by stirring at-60℃for 2 hours, followed by adding dropwise triisopropylborate (2.9 g,15.4 mmol) for 30 minutes, followed by slowly heating to room temperature (20 ℃) and stirring for 30 minutes. A mixture of 3g of acetic acid and 15g of water was added dropwise to terminate the reaction. After the addition, stirring at room temperature for 30 minutes. The organic solvent was distilled off, a little water was added, stirred at room temperature for 15 minutes, filtered, and the cake was washed with water and dried under vacuum at 70℃to give 2.1g of solid. Yield 80.22%, HPLC purity: 98.12%.
ESI-MS:m/z=188.1 (M+H) + 。
Step 3: preparation of intermediate e
A mixed solution of compound d (2.59 g,10.0 mmol), pd (amphos) Cl2 (107.5 mg,0.15 mmol) in 25ml of t-amyl alcohol was taken, heated to 85℃and a reaction was carried out at 85℃for 1 hour after about 1 hour with dropwise addition of a mixed solution of compound c (2.22 g,11.9 mmol), sodium carbonate (3.2 g,30.2 mmol) and 25ml of water. Cooling to room temperature, adding EA/water, extracting, separating out water layer, washing organic layer with water and saturated salt water, drying with anhydrous sodium sulfate, filtering, and evaporating solvent. Purification by column chromatography gave 2.4g of intermediate e. Yield 74.59%, HPLC purity: 98.63%.
ESI-MS:m/z=322.1 (M+H) + 。
Step 4: preparation of intermediate f
Compound e (1.87 g,5.80 mmol), anhydrous lithium chloride (1.3 g,30.7 mmol), p-toluenesulfonic acid monohydrate (2.2 g,11.6 mmol) and 20ml of isopropanol were taken and mixed, and reacted under reflux with heating for 16 hours. Cooled to room temperature, half of the solvent was distilled off, 30ml of water was added, stirred at room temperature for 15 minutes, filtered, and the cake was washed with water and dried under vacuum at 70℃to give 1.61g of solid. Yield: 90.21%, HPLC purity: 96.43%.
ESI-MS:m/z=308.1 (M+H) + 。
Step 5: preparation of intermediate h
A25 ml reaction flask was charged with compound f (803 mg,1.70 mmol), tetramethylguanidine (681 mg,5.91 mmol), isopropanol 6ml, acetone 1.5ml, and stirred at room temperature for 15 minutes, compound g (684 mg,1.9 mmol) was added, and the reaction was stirred at room temperature overnight. The next day, water is added to terminate the reaction, EA is added to extract, the water layer is separated, the organic layer is washed with saturated ammonium chloride, water, saturated saline water and anhydrous sodium sulfate in sequence, the mixture is dried, filtered, the solvent is evaporated, and the chromatographic column is used for separating and purifying, and the product is collected to obtain 832mg of pure product. The yield thereof was found to be 83.37% and the purity thereof was found to be 98.32%.
ESI-MS:m/z=587.1(M+H) + 。
Step 6: preparation of intermediate j
A25 ml reaction flask was charged with compound h (587 mg,1 mmol), methanol 8ml, dissolved with stirring and cooled to 0deg.C. Lithium hydroxide monohydrate (84 mg,2 mmol) was weighed and dissolved in 4ml of water, and the mixture was added dropwise to a reaction flask and reacted at room temperature for 2 hours. Adding water to terminate the reaction, adjusting pH to weak acidity with 5% citric acid, adding EA to extract, separating water layer, washing organic layer with water, saturated NaCl, drying with anhydrous sodium sulfate, filtering, evaporating solvent, and performing column chromatography to obtain 432mg of intermediate j with yield of 81.36% and purity of 98.30%.
ESI-MS:m/z=531.1 (M+H) + 。
Step 7: preparation of (S) -4- (2- (4- (5-chloro-2- (1H-tetrazol-1-yl) phenyl) -3- (methoxy-d 3) -6-oxopyridazin-1 (6H) -yl) butyramide) -2-fluoro-N- (methyl-d 3) benzamide (Compound 1)
50ml of reaction flask was charged with intermediate j (0.3 g,0.57 mmol), DMF 3ml, deuterated methylamine hydrochloride (48.2 mg,0.68 mmol), EDCI (218.7 mg,1.14 mmol), HOBT (154 mg,1.14 mmol), cooled to 0deg.C, DIPEA (295 mg,2.28 mmol) was added dropwise, reacted at room temperature for 12h, and the starting material was completed. The reaction solution was added to cold water, extracted twice with ethyl acetate, washed twice with saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness to give 210mg of Compound 1, which was purified on a silica gel column with a yield of 67.35% and a purity of 98.80%.
ESI-MS:m/z=547.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ: 10.76 (s, 1H), 9.12 (s, 1H), 8.10 (s, 1H), 7.90 – 7.76 (m, 3H), 7.71 – 7.60 (m, 2H), 7.37 (dd, J = 8.6, 2.0 Hz, 1H), 7.13 (s, 1H), 5.52 (s, 1H), 2.10 (d, J = 7.1 Hz, 2H), 0.79 (t, J = 7.2 Hz, 3H)。
Comparative example 1: preparation of (S) -4- (2- (4- (5-chloro-2- (4- (trifluoromethyl) -1H-1,2, 3-triazol-1-yl) phenyl) -5-methoxy-2-oxopyridin-1 (2H) -yl) butyramide) -2-fluorobenzamide
Synthesized according to the method described in patent CN108026072B, purity: 98.5%.
ESI-MS: m/z =593.1(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ: 10.78 (s, 1H), 9.14 (s, 1H), 7.88 – 7.77 (m, 3H), 7.72 – 7.61 (m, 2H), 7.55 (d, 2H), 7.37 (dd, 1H), 7.13 (s, 1H), 6.54 (s, 1H), 5.52 (dd, 1H), 3.25 (s, 3H), 2.18 – 2.00 (m, 2H), 0.78 (t, 3H)。
Test example 1: inhibition of coagulation factor FXIa
1. Test sample
Example compound 1 and comparative example 1.
2. Test procedure
1) Experiment buffer (50 mM HEPES,5mM KCl,145mM NaCl,1mg/ml PEG8000, pH 7.4) was prepared and equilibrated to room temperature.
2) Preparing 10X compound working solution.
3) Preparing 0.8nM Human FXIa working solution (2X), and mixing.
4) Add 20. Mu.L of FXIa working fluid from step 3) to all experimental wells of 384 well plates (Coring, 3702), 200g, RT, centrifuge for 10s.
5) Add 4. Mu.L of the compound working solution from step 2) to the corresponding experimental well in 384 well plates, 200g, RT, centrifuge for 10s, and then incubate the plates at 25℃for 20min.
6) Preparing 750 mu M S-2366 working solution (2.5X), and uniformly mixing for later use.
7) mu.L of the S-2366 working solution from step 6) was added to all experimental wells in 384-well plates, 200g, RT, centrifuged for 10S, and the plates were incubated at 37℃for 45min.
8) After incubation was completed, absorbance at OD405nm was read using EnVision and data was collected.
Setting 5 concentrations, namely: 200nM, 40nM, 8nM, 1.6nM, 0.32nM, detection IC 50 Values.
3. Data analysis
1) Z’ factor = 1-3*(SD Max +SD Min )/(Mean Max -Mean Min );
2) CV Max = (SD Max /Mean Max )*100%;
3) CVMin = (SD Min /Mean Min )*100%;
4) S/B = Singal/Background;
5) Blank control: 0.1% DMSO; positive control, comparative example 1;
6)IC 50 the calculation formula of (2) is Y=bottom+ (Top-Bottom)/(1+10 ((LogIC) 50 -X)*HillSlope))。
X is the log value of the compound concentration; y is Inhibition%.
4. Test results
The test results are shown in the following table, and the results show that: the in vitro inhibition activity of the compounds of the invention against FXIa was comparable to that of the compound of comparative example 1 at equimolar concentrations.
。
Test example 2: determination of in vitro anticoagulation of human plasma
1. Test sample
Example compound 1 and comparative example 1.
2. Test method
And (3) using a sodium citrate (1:9) anticoagulation tube, immediately mixing the blood with an anticoagulant fully and uniformly after collecting the blood of a healthy person, centrifuging at 4000r/min for 15 minutes at normal temperature, sucking a plasma sample by using a pipette after centrifugation, and freezing (-80 ℃) for standby.
Weighing a proper amount of compound, and preparing 10-100 mM mother liquor by using 100% DMSO (the concentration of the specific mother liquor is determined according to the nature of the compound); preparing working solutions (specifically: 0, 0.3, 1, 3, 10, 30, 60, 100, 300 μm) with different concentrations by taking healthy human blood plasma as solution, and fully and uniformly mixing; APTT determination was performed on the machine (model CS-2000I) after incubation at 37℃for 3 min.
3. Data processing
Curve fitting was performed using GraphPad Prism software to calculate the EC150 value, i.e., the effective concentration of the compound corresponding to 50% extension of APTT relative to the blank.
4. Test results
The results are shown in the following table, and the APTT EC150 of compound 1 tested is superior to that of the compound of comparative example 1.
Test example 3: rat pharmacokinetic study
1. Test sample
Example compound 1 and comparative example 1.
2. Test object preparation method and environmental requirements
The preparation of the test substances is carried out on a conventional working table of the preparation room.
Preparing stock solution of the building method: prepared according to the dispensing protocol, 1.00mg/mL stock solutions of example compound 1 and comparative example 1 were prepared using methanol as the solvent.
Preparation of rat dosing solution: prepared by using 0.5% CMC-Na as solvent. The oral administration concentration is 30mg/mL.
3. Test procedure
(1) Administration and sample collection
Rats were fasted for 12h before dosing and were free to drink water. The experiment used 12 SD rats, each half of male and female, divided into 2 groups of 6.
Collecting blank blood before administration, and pressing after administrationTaking blood at a preset time point:2min、5min、10min、15min、30min、 45min、1h、2h、3h、5h、7h、24h,blood was collected at about 0.5mL, placed in EDTA-K2 tube, centrifuged to separate plasma, and stored at-80 ℃.
(2) Animal handling
At the end of the experiment, all animals were euthanized according to institutional SOP.
(3) Instrument for measuring and controlling the intensity of light
Liquid phase-mass spectrometry analysis system (LC-MS/MS) comprising Shimadzu LC-20AD series binary pump and SIL-20AC autosampler, AB company API-4000Q-Trap mass spectrum detector (containing ESI ion source), chromatographic column: ODS-C18 (4.6X150 mm, 3 μm).
(4) Sample processing
Standard curve sample treatment: a series of working fluids containing different concentrations of comparative example 1 and compound 1 were prepared. Taking 20 mu L of working solution, adding 100 mu L of blank plasma sample, vortex mixing, adding 300 mu L of acetonitrile solution containing 40 ng/mL of propranolol internal standard, vortex mixing, centrifuging at 4 ℃ for half an hour at 14000g, and taking supernatant for LC-MS/MS detection.
Rat plasma sample treatment: 20. Mu.L of acetonitrile was taken, 100. Mu.L of plasma sample was added, vortexed and mixed, 300. Mu.L of acetonitrile solution containing 40 ng/mL of propranolol as an internal standard was further added, vortexed and mixed, and centrifuged at 4℃and 14000g for half an hour, and the supernatant was taken for detection.
(5) Pharmacokinetic analysis
The pharmacokinetic parameters were calculated using DAS 2.0 software based on the plasma concentration data of the drug.
4. Results
The results of pharmacokinetic studies with oral administration in rats are shown in the following table, with superior absorption and AUC for example compound 1 compared to comparative example 1 (0-t) And Cmax, while having a shorter half-life, with rapid elimination of pharmacokinetic profile, and lower safety risk for potential bleeding.
The above embodiment is only one of the preferred embodiments of the present invention, and should not be used to limit the scope of the present invention, but all the insubstantial modifications or color changes made in the main design concept and spirit of the present invention are still consistent with the present invention, and all the technical problems to be solved are included in the scope of the present invention.
Claims (9)
1. A compound of formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof:
2. the compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 1, wherein the salt is a metal salt.
3. A compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 2, wherein the metal salt is selected from sodium, potassium, calcium, lithium, magnesium salts.
4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3, a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the composition further comprises a pharmaceutically acceptable carrier and/or adjuvant.
5. A process for the preparation of a compound according to any one of claims 1 to 3, a stereoisomer or a pharmaceutically acceptable salt thereof, which comprises the following route:
。
6. use of a compound according to any one of claims 1 to 3, a stereoisomer or a pharmaceutically acceptable salt thereof, or a composition according to claim 4 for the preparation of a medicament for the treatment and/or prevention of diseases associated with the F xi a receptor.
7. The use according to claim 6, wherein the disease associated with the F xi a receptor is selected from thrombosis and thromboembolic related disorders.
8. Use according to claim 6, wherein the diseases related to the F xi a receptor are selected from cerebrovascular arterial diseases and/or peripheral arterial diseases.
9. Use according to claim 6, wherein the diseases related to the F-xi a receptor are selected from Transient Ischemic Attacks (TIA) or ischemic strokes, including cardiac strokes, strokes such as those caused by atrial fibrillation, non-cardiac strokes, strokes such as lacunar-tive strokes, strokes caused by aortic or arteriolar diseases, or strokes caused by adventitious causes, cryptogenic strokes, embolic strokes of adventitious origin, or events of thrombotic and/or thromboembolic origin leading to strokes or TIA, and/or conditions of the peripheral arteries leading to peripheral arterial diseases, including peripheral arterial occlusion, acute limb ischemia, amputation, reocclusion and restenosis following interventions such as angioplasty, stent implantation or surgery and bypass, and/or stent thrombosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311149889.5A CN117164562A (en) | 2023-09-07 | 2023-09-07 | Oxopyridazine compound and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311149889.5A CN117164562A (en) | 2023-09-07 | 2023-09-07 | Oxopyridazine compound and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117164562A true CN117164562A (en) | 2023-12-05 |
Family
ID=88935124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311149889.5A Pending CN117164562A (en) | 2023-09-07 | 2023-09-07 | Oxopyridazine compound and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117164562A (en) |
-
2023
- 2023-09-07 CN CN202311149889.5A patent/CN117164562A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3573983B1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
EP3630755B1 (en) | 5-methyl-1,3,4-oxadiazol-2-yl compounds | |
JP6861858B2 (en) | SSAO inhibitor | |
RU2257381C2 (en) | Diazepane derivative, pharmaceutical composition comprising thereof and inhibitor of blood coagulation activated factor x | |
CN116082303A (en) | Novel oxopyridines, intermediates and uses thereof | |
CN116262734A (en) | Novel oxo-pyridine compound and preparation method and application thereof | |
CN110092779B (en) | Substituted phenyl compound and application thereof | |
IL280598B1 (en) | 2,6-diamino pyridine compounds | |
CN116874469B (en) | Oxo-pyridine compound, intermediate, preparation method and application thereof | |
CN116262736A (en) | Novel oxo-pyridine compound and preparation method and application thereof | |
JPS6013788A (en) | Novel coumarin derivative | |
LU84770A1 (en) | BENZOAZACYCLOALKYL-SPIRO-IMIDAZOLIDINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
CN116262740A (en) | Novel oxo-pyridine compound and preparation method and application thereof | |
FR2758329A1 (en) | New imidazole-4-butane-boronic acid derivatives | |
CA2089349C (en) | New pyrolidine derivatives, process for their preparation and pharmaceutical composition holding same | |
CN117164562A (en) | Oxopyridazine compound and preparation method and application thereof | |
CN116947818B (en) | Oxo-pyridine compound, intermediate, preparation method and application thereof | |
EP2917204B1 (en) | Derivatives of 1h-indole-3-carboxamide and their use as p2y12 antagonists | |
WO1996015117A1 (en) | Optically active compound | |
CN115427043B (en) | Medical application of FXIa inhibitor compound or salt thereof | |
CN117164523A (en) | Oxo-pyridine compound and preparation method and application thereof | |
JP7404553B2 (en) | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compound | |
CN117164561A (en) | Oxo pyrimidine compound and preparation method and application thereof | |
CN117164563A (en) | Novel oxo-pyrimidine compound and preparation method and application thereof | |
CN117164566A (en) | Novel oxopyridazine compound and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |